BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
BRISTOL MYERS SQUIBB CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$58.83−0.92 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
71.1%−1.2 pts over 5 years
Net margin
14.6%+35.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.2% | +1.4% | +2.5% | +11.3% | |
| Gross profit | -0.2% | -1.7% | +2.2% | +10.5% | |
| Net income | – | +3.7% | – | +16.2% | |
| EPS, diluted | – | +5.5% | – | +14.0% | |
| Free cash flow | -7.9% | +2.4% | -0.7% | +25.9% | |
| Dividend per share | +2.9% | +4.4% | +6.2% | +5.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 29.3% | -20.2% | 40.5% | |
| Return on assets | 13.6% | -7.3% | 7.7% | |
| Current ratio | 1.55 | 1.58 | 1.26 | |
| Debt to equity | 0.41 | 1.34 | 2.44 | |
| Inventory turnover | 4.0× | 3.7× | 5.3× | |
| Capex to revenue | 6.3% | 1.8% | 2.7% | |
| Diluted shares | 1.68B | 2.26B | 2.04B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Bristol Myers Squibb generated $72.48B from operations and spent $48.98B on capital expenditure, dividends and share buybacks. 12% of that went back into the business.
Generated
$72.48B
Used
$48.98B
Capital expenditure$5.86B12%Dividends$23.68B48%Share buybacks$19.44B40%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin14.6%
×Asset turnover0.53×
×Equity multiplier5.25×
=Return on equity, FY202540.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 14.6% | 0.53× | 5.25× | 40.5% |
| FY2024 | -18.5% | 0.51× | 4.10× | -39.1% |
| FY2023 | 17.8% | 0.47× | 3.17× | 26.5% |
| FY2022 | 13.7% | 0.45× | 3.08× | 18.9% |
| FY2021 | 15.1% | 0.41× | 3.09× | 19.0% |
| FY2020 | -21.2% | 0.34× | 2.78× | -20.2% |
| FY2019 | 13.2% | 0.32× | 2.51× | 10.5% |
| FY2018 | 21.8% | 0.66× | 2.66× | 38.2% |
| FY2017 | 4.8% | 0.62× | 2.41× | 7.2% |
| FY2016 | 22.9% | 0.59× | 2.15× | 29.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$7.05B
- Cash generatingOperating cash flow above zero$14.16B
- Return on assets improvedROA up on the prior year-9.4% → 7.6%
- Earnings backed by cashOperating cash flow above net income$14.16B vs $7.05B
- Less leverageLong-term debt to assets fell51.4% → 47.6%
- Better liquidityCurrent ratio rose1.25 → 1.26
- No dilutionShare count did not rise2.03B → 2.04B
- Gross margin improvedGross margin up on the prior year71.08% → 71.08%
- More efficientAsset turnover rose0.51 → 0.52